For patients with heart failure, a greater focus on medication management may be needed in order to mitigate exacerbations caused by certain drugs.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

After adjusting for potential confounders (age, sex, race, use of birth control, pregnancy), findings showed propranolol use was associated with a significant reduction in the risk of stroke among ...

In clinical practice guidelines jointly issued by the US Department of Veterans Affairs and US Department of Defense, updated recommendations are presented for the management of stroke rehabilitation.

COVID-19 infection, compared with influenza, is associated with increased myocarditis rates among adults in the United States.

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.

In one of his first presidential actions on Monday, President Trump issued an executive order withdrawing the United States from the World Health Organization.

Kansas health officials are tackling the largest tuberculosis (TB) outbreak in US history, with 67 confirmed cases since the start of 2025.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.